#United States #New York #Securities Fraud #Rosen Law Firm #INOVIO Pharmaceuticals

Investors Encouraged to Lead Class Action Against Inovio Pharmaceuticals

In a decisive move, the Rosen Law Firm, recognized globally for its dedication to investor rights, has alerted purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities to an important deadline regarding a class action lawsuit. This pertains specifically to those who bought shares between October 10, 2023, and December 26, 2025. The timeline is of utmost importance, as April 7, 2026, is the cut-off date for any potential lead plaintiff to step forward in this case.

Understanding the Class Action

For investors who purchased Inovio securities during the specified period, joining the class action could mean eligibility for compensation without incurring any costs upfront thanks to a contingency fee structure. This means that investors will not have to pay legal fees unless they win the case, making it easier for many to participate and share in any potential monetary recovery.

Investors interested in joining this class action are encouraged to visit Rosen Law Firm’s website or to reach out to Phillip Kim, Esq. via a toll-free phone line for more information. There has already been a lawsuit filed, and those interested in taking the lead role must move quickly—April 7, 2026, marks the latest date for such a motion to be made.

About Rosen Law Firm

The law firm emphasizes the importance of selecting competent counsel experienced in leading securities class actions. Many firms that might issue notices about such lawsuits lack the necessary expertise and may only act as intermediaries, which can dilute the quality of representation that investors receive. Rosen Law Firm stands out for its track record, particularly as it focuses on maximizing recovery for its clients. Notably, it achieved the largest securities class action settlement against a Chinese company, exhibiting its capability in significant cases. The firm has consistently ranked high in securities class action settlements, having secured hundreds of millions for investors over the years.

Details of the Case

The current lawsuit arises from a series of alleged false and misleading statements made by Inovio’s executives during the class period. According to the case, the company failed to disclose several critical issues, including deficiencies in the manufacturing processes of its CELLECTRA device and uncertainties regarding its INO-3107 Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). These oversights reportedly led to inflated representations of the product's regulatory and commercial viability.

When these facts were eventually revealed to the public, investors experienced significant financial harm, which underscores the case's significance. Investors now have the option to join this collective effort for remedy and accountability.

Next Steps for Investors

To be considered as a lead plaintiff, interested investors must act by the April 7, 2026, deadline. They may also choose to remain anonymous and not actively participate in the suit, but their ability to share in any future compensation won't rely on their lead plaintiff status. As the situation unfolds, potential class members are recommended to keep abreast of developments through the law firm’s social media channels as well.

In conclusion, this situation presents a critical opportunity for Inovio shareholders to reclaim some of their losses through collective action and leverage the expertise of a reputable law firm. Investors are urged to act swiftly to protect their rights and secure potential compensation for their investments.